TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)

TD Cowen analyst Stacy Ku reiterated a Buy rating and $30.00 price target on BioCryst Pharma (NASDAQ: BCRX).

The analyst comments "Q4 Orladeyo reached $151MM (+3% Q/Q), in line with pre-announcement. For 2026,mgmt reiterated rev guidance of $625-645MM (+11-15%), which reflects +12%Y/Ygrowth for US sales, driven by still steady patient accumulation, solid retention despitenew injectable entrants, and the pediatric expansion. Orladeyo & navenibart eachrepresent $1B peak drugs & solidifies BCRX's position in HAE."

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $7.55 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Kotak Upgrades Honasa Consumer Ltd (HONASA:IN) to Buy (1)
• Syensqo SA (SYENS:BB) PT Raised to EUR100 at JPMorgan